We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+16.29%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$8.82B
AUM Growth
+$974M
Cap. Flow
+$85.6M
Cap. Flow %
0.97%
Top 10 Hldgs %
37.09%
Holding
149
New
20
Increased
26
Reduced
29
Closed
13

Top Buys

Rank Stock Value
1
CNC icon
Centene
CNC
+$111M
2
AGN.PRA
Allergan plc
AGN.PRA
+$73.1M
3
MRK icon
Merck
MRK
+$69.9M
4
AET
Aetna Inc
AET
+$63.6M
5
VTRS icon
Viatris
VTRS
+$52.4M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$148M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$72.3M
3
AGN
Allergan plc
AGN
+$68.1M
4
ISRG icon
Intuitive Surgical
ISRG
+$67.6M
5
SHPG
Shire pic
SHPG
+$53.4M

Sector Composition

Rank Sector Weight
1 Healthcare 92.96%
2 Financials 2.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JAZZ icon
51
Jazz Pharmaceuticals
JAZZ
$16.2B
$53.9M 0.61%
371,400
– –
VTRS icon
52
Viatris
VTRS
$20.9B
$50.7M 0.57%
+1,300,000
New +$52.4M
UNH icon
53
UnitedHealth
UNH
$387B
$48.6M 0.55%
296,400
– –
LUMO
54
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$48M 0.54%
221,300
– –
SYK icon
55
Stryker
SYK
$134B
$41.6M 0.47%
316,300
– –
ACAD icon
56
Acadia Pharmaceuticals
ACAD
$4.43B
$40.2M 0.46%
+1,169,000
New +$41.3M
GBT
57
DELISTED
Global Blood Therapeutics, Inc.
GBT
$40M 0.45%
+1,084,500
New +$27.3M
ISRG icon
58
Intuitive Surgical
ISRG
$128B
$38.6M 0.44%
453,600
-855,900
-65% -$67.6M
COO icon
59
Cooper Companies
COO
$14.2B
$38.1M 0.43%
763,200
-237,200
-24% -$11.3M
NTLA icon
60
Intellia Therapeutics
NTLA
$1.49B
$37.5M 0.43%
2,662,180
– –
DERM
61
DELISTED
Dermira, Inc.
DERM
$34.9M 0.4%
1,023,673
+598,073
+141% +$19.3M
ONC
62
BeOne Medicines Ltd
ONC
$34B
$33.1M 0.38%
903,700
– –
ASMB icon
63
Assembly Biosciences
ASMB
$507M
$32M 0.36%
104,775
-11,650
-10% -$2.86M
SRPT icon
64
Sarepta Therapeutics
SRPT
$1.61B
$31.2M 0.35%
+1,054,300
New +$32.6M
MNTA
65
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$28.2M 0.32%
2,109,068
-842,900
-29% -$13.2M
SEM
66
DELISTED
Select Medical
SEM
$27.9M 0.32%
3,872,173
+2,328,167
+151% +$16.9M
RDUS
67
DELISTED
Radius Health, Inc.
RDUS
$27.2M 0.31%
+704,100
New +$29.5M
OBSV
68
DELISTED
ObsEva SA Ordinary Shares
OBSV
$27.1M 0.31%
+2,605,531
New +$32M
RNAC icon
69
Cartesian Therapeutics
RNAC
$226M
$26.4M 0.3%
61,427
– –
BLUE
70
DELISTED
bluebird bio
BLUE
$25.8M 0.29%
21,909
– –
IOVA icon
71
Iovance Biotherapeutics
IOVA
$2.04B
$25.2M 0.29%
3,382,900
– –
LKFT
72
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
$24.4M 0.28%
283,500
– –
IMGN
73
DELISTED
Immunogen Inc
IMGN
$23.6M 0.27%
6,095,647
– –
CHRS icon
74
Coherus Oncology
CHRS
$224M
$22.9M 0.26%
1,084,400
+234,300
+28% +$5.76M
OTIC
75
DELISTED
Otonomy, Inc.
OTIC
$22.7M 0.26%
1,850,094
– –
1 2
3
4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2017 Portfolio in Review

As of Q1 2017, OrbiMed held 149 positions worth $8.82B, up 12% from $7.85B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

OrbiMed's Q1 2017 filing shows 20 new, 26 increased, 29 reduced and 13 closed positions. Its largest new stake was Centene: 3,311,400 shares worth $118M. The largest sale was Amgen, an estimated $148M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Financials.

  • OrbiMed's largest Q1 2017 buy was Centene: 3,311,400 shares worth $118M.
  • OrbiMed added most to Merck in Q1 2017, an estimated $69.9M increase.
  • OrbiMed's biggest Q1 2017 reduction was Amgen, cutting an estimated $148M.
  • OrbiMed fully exited Molina Healthcare in Q1 2017, selling an estimated $26.9M.
  • OrbiMed's ten largest holdings make up 37% of its $8.82B portfolio in Q1 2017.
  • OrbiMed opened 20 new positions and closed 13 in Q1 2017.
  • OrbiMed's portfolio value rose 12% quarter-over-quarter to $8.82B.

Based on OrbiMed's 13F filing for Q1 2017, filed 15 May 2017.